Archives
-
p-Cresyl Sulfate and Aortic Valve Calcification
2026-09-01
The 2026 reference study identifies p-cresyl sulfate as a direct enhancer of calcification in aortic valvular interstitial cells and connects this effect with HIF-1α activation, klotho loss, and disrupted SIRT1-associated signaling. Its porcine cell and rat chronic kidney disease models suggest that klotho supplementation or SIRT1 activation can reduce PCS-associated NF-κB/RUNX2 signaling, while also highlighting important limits for translation to human calcific aortic valve disease.
-
Metformin, EDH, and Microvascular Protection in Colitis
2026-09-01
A 2025 European Journal of Pharmacology study identifies endothelium-dependent hyperpolarization as a major pathway for metformin-induced relaxation of intestinal resistance vessels. Its findings connect endothelial calcium signaling through PLC/IP3/IP3R, store-operated calcium entry, and TRPV4 channels with preservation of mucosal perfusion in experimental colitis.
-
OCT2 and MATE1 Inhibition by 5-HT3 Antagonists
2026-08-31
George et al. evaluated how five 5-HT3 antagonist antiemetics inhibit the renal organic cation transport system formed by OCT2 and MATE1. Their cell-based experiments identified compound-specific inhibition patterns and showed that ondansetron can disrupt coordinated basolateral-to-apical transport, providing a mechanistic basis for potential interactions involving renally secreted cationic drugs.
-
Streptozotocin: From β-Cell Injury to Neuropathy
2026-08-31
Streptozotocin (STZ) is more than a tool for creating hyperglycemia: it is a mechanistically defined perturbation that can connect β-cell loss with inflammatory complications such as painful diabetic neuropathy. This thought-leadership guide shows how translational researchers can use STZ with greater experimental precision, integrate TBK1–microglia biology, and design models that better support therapeutic decisions.
-
Cyclic Pifithrin-α Hydrobromide: Assay Logic
2026-08-30
Cyclic Pifithrin-α hydrobromide is a p53 inhibitor for separating p53-dependent transcription from downstream cell fate decisions. This article connects its use to neuroinflammation research while defining practical controls, assay boundaries, and interpretation standards.
-
OCT2 and MATE1 Inhibition by Antiemetics
2026-08-29
George et al. systematically compared five 5-HT3 antagonists as inhibitors of the renal organic cation transport pathway mediated by OCT2 and MATE1. Their combination of transporter-specific uptake assays and a directional MDCK transcellular model shows that antiemetics can differentially disrupt cationic drug secretion, supporting closer evaluation of transporter-mediated drug interactions.
-
Tofacitinib citrate: Immune Assay Workflows
2026-08-28
Build dose-resolved immune and endothelial assays with Tofacitinib citrate (CP-690550 citrate), from JAK-STAT pathway studies to cytokine-driven vascular models. Learn how to separate anti-inflammatory activity from adhesion, coagulation, and cytotoxicity phenotypes.
-
One-step TUNEL Cy3 Apoptosis Detection Kit Guide
2026-08-28
This scenario-based guide explains how the One-step TUNEL Cy3 Apoptosis Detection Kit, SKU K1134, can address common problems in DNA fragmentation and apoptosis workflows. It covers assay principles, sample compatibility, controls, interpretation, and practical vendor-selection criteria for research teams.
-
The 4Q Principle for Stable mRNA Delivery
2026-08-27
The 2024 Chemistry of Materials study introduces a 4Q framework that treats mRNA delivery as a sequence of stability, diffusion, cellular entry, and intracellular release steps. Its disulfide-containing polycatechol, PBD, produced room-temperature-stable polyplexes and substantially higher in vivo fluorescence than a jetPEI benchmark, offering a practical design logic for nonviral mRNA vectors.
-
SPRTN Ubiquitin Binding and DPC Proteolysis
2026-08-27
A 2024 bioRxiv preprint identifies a ubiquitin-binding interface within the catalytic SprT region of SPRTN and links ubiquitin-chain recognition to selective DNA-protein crosslink proteolysis. The work provides a mechanistic explanation for how SPRTN distinguishes polyubiquitinated DPCs from unmodified lesions and activates proteolysis approximately 67-fold more strongly.
-
DPPH Radical: Mechanism, Assay & Evidence
2026-08-26
DPPH, or 2,2-Diphenyl-1-Picrylhydrazyl, is a nitrogen-centered stable radical used for rapid in vitro antioxidant screening. Its violet-to-yellow reduction signal supports compound and extract ranking, but it does not by itself establish cellular antioxidant efficacy or a therapeutic mechanism.
-
Formononetin Protects Against Oxaliplatin Neurotoxicity
2026-08-26
The reference study identifies formononetin as a candidate neuroprotectant that reduces oxaliplatin-induced oxidative stress and neuronal apoptosis through the Nrf2/HO-1 pathway. Its most important translational finding is that protection of dorsal root ganglion neurons was achieved without reducing oxaliplatin or paclitaxel anticancer activity in the tested cancer cell models.
-
Jasplakinolide: Actin Polymerization Inducer
2026-08-25
Jasplakinolide is a membrane-permeable actin polymerization inducer that also stabilizes pre-existing F-actin. Its competitive binding to actin, ion-dependent behavior, and DMSO-compatible handling make it a useful actin cytoskeleton research tool when paired with appropriate controls.
-
131I-MIBG–PARP Synergy in PPGL Models
2026-08-25
Song et al. investigated whether the radionuclide therapy 131I-MIBG could work synergistically with the PARP inhibitor fluzoparib in norepinephrine transporter-overexpressing pheochromocytoma and paraganglioma models. The combination increased G2/M arrest and apoptosis, while SDHB suppression selectively heightened sensitivity to fluzoparib rather than changing the response to 131I-MIBG.
-
Estradiol Benzoate: From Receptor Signal to Translation
2026-08-24
A mechanistic and translational guide to using Estradiol Benzoate as an estrogen receptor alpha agonist, with practical assay design, quality considerations, and lessons from structure-based NSP15 inhibitor screening.